Skip to main content
. Author manuscript; available in PMC: 2019 Oct 14.
Published in final edited form as: Am J Hematol. 2015 Jul;90(7):639–646. doi: 10.1002/ajh.24016

Figure 1.

Figure 1.

Outcomes of older AML patients treated with different induction strategies. (A) Overall survival of older AML patients following induction with intensive chemotherapy (IC) or epigenetic (Epi) therapy. Median survival of the IC group was 10.7 months as compared with 9.1 months in the Epi-treated patients (P = 0.012). (B) Leukemia-free survival of patients following IC or epigenetic therapy. Median survival of IC group was 29.2 months as compared with 9.2 months (P = 0.090). (C) Overall survival of older AML patients following induction with IC or 10 days of decitabine (Dec10). Median survival of the IC group was 10.7 months as compared with 8.0 months in the Dec10-treated patients (P = 0.026). (D) Leukemia-free survival of patients following induction with IC or Dec10. Median survival time of IC group was 29.2 months as compared with 10.3 months following Dec10 treatment (P = 0.239). Epi (solid line), epigenetic therapy; IC (dotted line), intensive chemotherapy; median, median overall survival.